Associated Papers
Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer.
Ochman B et al.
International Journal of Molecular Sciences, 2026
Predictive Molecular Biomarkers of Bladder Cancer Identified by Next-Generation Sequencing-Preliminary Data.
Myszka A et al.
Journal of Clinical Medicine, 2024
Association of mutation profiles with metastasis in patients with non-small cell lung cancer.
Li Y et al.
Frontiers in Oncology, 2024
Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer.
Wu JB et al.
Biomedical Reports, 2023
Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania.
Afrăsânie VA et al.
International Journal of Molecular Sciences, 2023
MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.
Pang JM et al.
Plos One, 2023
Discrimination of Single-Nucleotide Variants Based on an Allele-Specific Hybridization Chain Reaction and Smartphone Detection.
Lázaro A et al.
Acs Sensors, 2022
Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population With Non-small Cell Lung Cancer.
Kahraman Çetin N et al.
Balkan Medical Journal, 2021
Validation and clinical application of a targeted next-generation sequencing gene panel for solid and hematologic malignancies.
Prieto-Potin I et al.
Peerj, 2020
BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas.
Colombino M et al.
Journal of Clinical Medicine, 2019
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Wojas-Krawczyk K et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University, 2019
Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia.
Singhi AD et al.
Gut, 2018
Metastases risk in thin cutaneous melanoma: prognostic value of clinical-pathologic characteristics and mutation profile.
Richetta AG et al.
Oncotarget, 2018
Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients.
Guo F et al.
Scientific Reports, 2018
Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.
Shimura T et al.
Oncotarget, 2018
Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets.
Chen S et al.
Oncology Letters, 2016
Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
Magliacane G et al.
Oncotarget, 2015
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
Kawazoe A et al.
Bmc Cancer, 2015
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.
Emile JF et al.
Blood, 2014
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing.
Portier BP et al.
American Journal of Clinical Pathology, 2014
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.
Jovanovic B et al.
The Journal of Investigative Dermatology, 2010